CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)
TREATMENT OPTIONS IN CHINA

Many patients with CLL do not need treatment at diagnosis. Active surveillance — sometimes called watch-and-wait — is the right approach for early-stage, asymptomatic disease, and starting therapy too early does not improve outcomes. Treatment is generally indicated when there is significant or progressive symptoms (fatigue, night sweats, weight loss), bulky or rapidly enlarging lymph nodes, progressive splenomegaly, autoimmune complications not responding to standard therapy, or progressive marrow failure leading to anaemia or thrombocytopenia. The decision should be made by an experienced haematologist after considering disease tempo and patient factors — not by laboratory numbers alone.

Modern CLL treatment depends on genetic and molecular testing. Key tests include FISH for chromosome abnormalities (particularly 17p deletion and 11q deletion), TP53 mutation analysis, IGHV mutation status, and CD20 expression. TP53 mutation or 17p deletion identifies high-risk disease that responds poorly to chemoimmunotherapy and should be treated with targeted agents from the first line. IGHV unmutated status also predicts shorter response to chemoimmunotherapy. CancerFax sees many international cases where these tests were not done before treatment started — a structured second opinion at this stage often changes the plan significantly.

BTK inhibitors BTK inhibitors are now the cornerstone of CLL treatment for many patients. Ibrutinib was the first; acalabrutinib and zanubrutinib are second-generation agents with cleaner side effect profiles, particularly fewer cardiovascular events. Zanubrutinib was developed in China and is widely available there at meaningfully lower cost than originator BTK inhibitors. Pirtobrutinib, a non-covalent BTK inhibitor, is increasingly used for patients who progress on covalent BTK therapy or develop BTK resistance mutations. BTK inhibitors are typically given as continuous oral therapy. BCL-2 inhibitor: venetoclax Venetoclax, a BCL-2 inhibitor, is a major advance in CLL care. It is most often combined with obinutuzumab (anti-CD20) as a fixed-duration first-line regimen — typically twelve months — that achieves deep remissions including undetectable MRD in many patients. In relapsed disease, venetoclax is often combined with rituximab. Tumour lysis syndrome is a real risk during dose ramp-up and requires careful monitoring. Anti-CD20 antibodies Obinutuzumab and rituximab are anti-CD20 monoclonal antibodies used as partners with venetoclax or, in selected patients, with chemotherapy or BTK inhibitors. Biosimilar rituximab is widely available in China at substantially lower cost than originator drug, and biosimilar obinutuzumab access is expanding. For patients facing long-term combination therapy, biosimilar economics can meaningfully change what is sustainable. Chemoimmunotherapy Chemoimmunotherapy — FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) — was the previous standard but is now reserved for selected younger fit patients with IGHV-mutated disease without TP53 abnormalities. For most modern patients, targeted therapy is preferred. Chemoimmunotherapy should not be given to patients with TP53 mutation or 17p deletion. CAR-T cell therapy CAR-T cell therapy is being actively developed in CLL, with lisocabtagene maraleucel (liso-cel) approved in some regions for relapsed or refractory disease after BTK and venetoclax. China has a strong trial pipeline for CD19 CAR-T in CLL, including for Richter transformation, and emerging dual-target platforms. Eligibility depends on prior therapy, fitness, and disease burden. CAR-T in CLL is most often considered after multiple lines of targeted therapy. Bispecific antibodies and clinical trials CD20-CD3 bispecific antibodies — epcoritamab and others — are being studied in CLL and Richter transformation, alongside novel BTK degraders and BCL-2 combinations. China has an active trial portfolio in this space, and clinical trials are often the most meaningful option for patients with double-refractory disease (failed BTK and venetoclax). Allogeneic transplant Allogeneic bone marrow transplant is now reserved for selected high-risk patients with limited remaining options after multiple targeted therapies and trials. Chinese transplant centres have particular experience with haploidentical (half-match) family donor transplants, which makes donor identification more accessible than HLA-matched unrelated donor searches in many countries.

Richter transformation is the conversion of CLL into an aggressive lymphoma — most commonly diffuse large B-cell lymphoma. It is a serious change that requires rapid diagnosis through PET-guided biopsy and structured treatment. Standard chemoimmunotherapy is often insufficient, and modern approaches combine R-CHOP-like regimens with targeted agents, BTK or PI3K inhibitors, bispecific antibodies, and CAR-T cell therapy. China's CAR-T and bispecific trial portfolio is particularly relevant here. CancerFax prioritises Richter transformation cases for rapid review.

Case review — diagnosis, genetic findings, prior treatment, and current status are reviewed to confirm whether the current pathway is optimal. Genetic testing access — if FISH, TP53, or IGHV testing has not been done, CancerFax helps arrange reliable testing internationally — these results often change the treatment plan. Hospital and trial matching — reports are shared with experienced Chinese haematology and CAR-T centres for structured feedback before any travel. Treatment planning — BTK inhibitor selection, fixed-duration venetoclax-obinutuzumab combinations, biosimilar options, and trial pathways are mapped against the patient's case. Continuity of care — communication with hospital teams, monitoring schedules, and follow-up after returning home are coordinated through a single point of contact.

Comprehensive CLL care in China is concentrated in major haematology centres in Beijing, Shanghai, Tianjin, Guangzhou, Suzhou, and other cities. The same treatment category may have different cost structures, trial access, and admission timelines depending on the centre. For most CLL patients, much of the care can be delivered through structured remote review, periodic in-person visits, and local infusion or oral therapy support. CancerFax helps patients identify the most relevant pathway — including when full travel is genuinely needed versus when structured remote management is appropriate.

Frequently Asked Questions

Answers to common questions from patients and families.